Balyasny Asset Management
RNAM

Balyasny Asset Management’s Avidity Biosciences RNAM Stock Holding History

Balyasny Asset Management’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-130,000
Closed -$2M – 2714
2023
Q1 		$2M Buy
+130,000
New +$2.86M 0.01% 1464

Other funds holding RNAM

CC
Corsicana & Co Corsicana, Texas $206M AUM 26.42% 1-Year Est. Return

Balyasny Asset Management's RNAM Position: Q1 2026 in Review

Balyasny Asset Management sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 6,040,590 shares — an estimated $436M sold.

Balyasny Asset Management first reported a position in RNAM in Q2 2021 and held it in 12 quarters. The position peaked at $436M in Q4 2025. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.

  • Balyasny Asset Management reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
  • Balyasny Asset Management sold 6,040,590 Avidity Biosciences shares in Q1 2026, an estimated $436M.
  • Balyasny Asset Management first reported a position in Avidity Biosciences in Q2 2021 and held it in 12 quarters.
  • Balyasny Asset Management's Avidity Biosciences position peaked at $436M in Q4 2025.
  • 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.